Sign in
XENE Stock Price, Chart, Stats & News
Xenon Pharmaceuticals Inc.
Save
Xenon Pharmaceuticals Inc. (XENE) does not currently pay a dividend.
3.59B
Market cap
–
Current P/E
–
Forward P/E
XENE chart
Fundamentals
Gross margin | -943.96% |
Operating margin | -4974.27% |
Pretax margin | -4598.59% |
Net margin | -4612.13% |
Effective tax rate | -0.29% |
ROA | -35.24% |
ROE | -55.81% |
D/E | 0.01x |
Interest coverage ratio | – |
XENE valuation
P/E | – |
P/S | 573.47x |
P/B | 7.42x |
P/CF | -15.47x |
P/FCF | -15.37x |
P/OCF | -15.47x |
PEG | 1.03x |
EV multiple | -12.50x |
About
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Similar securities
Based on sector and market capitalization
Report issue